Replies to post #90349 on Biotech Values

[DewDiligence]

NVS wins jury verdict in case alleging ONJ from Zometa:

http://www.reuters.com/article/2011/05/26/novartis-zometa-idUSN2619744320110526

The suit is one of an estimated 600 filed against the unit of Novartis AG in recent years blaming the company for suppressing information about adverse effects linked to Zometa and Aredia, another bone-strengthening drug.

…Hogan's is the fourth Zometa case to go to trial. In October 2010, a New Jersey superior court jury ruled in favor of Novartis. A jury in Montana state court awarded a plaintiff with the same jaw disease $3.2 million in October 2009, and in November, a federal jury in North Carolina awarded a North Carolina woman's family $12.8 million, later reduced to $1.26 million.

In AMGN’s phase-3 studies where Demosumab was tested against Zometa, Zometa had a lower incidence of ONJ (#msg-46432767).